🇺🇸 FDA
Patent

US 11124567

Anti-TREM2 antibodies and methods of use thereof

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 11124567 (Anti-TREM2 antibodies and methods of use thereof) held by DENALI THERAPEUTICS INC. expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
DENALI THERAPEUTICS INC.
Grant date
Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K2039/505, A61K2039/545